Divine Aleru, Microbiome Signatures Research Coordinator

Mendelian randomization identified causal links between 9 metabolites and ovarian cancer risk. Some metabolites promote, others protect against OC. These findings suggest potential biomarkers for diagnosis and treatment but require clinical validation.

A two-sample MR of 486 metabolites reports suggestive causal links across OC and histotypes, maps caffeine/arginine/TCA and alpha-linolenic pathways, and surfaces microbially influenced xenobiotics as potential biomarkers; findings require replication before translation.

This review explores how heavy metals, including cadmium, lead, and mercury, contribute to the development of female cancers by mimicking estrogen, inducing oxidative stress, and causing DNA damage. These findings highlight the need for further research to understand the molecular mechanisms involved and develop effective prevention strategies.

This study investigates how sub-chronic exposure to lead, cadmium, and cobalt induces multidrug resistance in ovarian cancer cells, highlighting the role of drug efflux transporters and reduced apoptosis in treatment resistance. These findings underscore the importance of environmental metal exposure in cancer therapy effectiveness.

The study examines the association between urinary concentrations of heavy metals (arsenic, cadmium, mercury, lead) and survival in patients with advanced high-grade serous ovarian cancer. High levels of these metals correlate with worse outcomes, particularly lead, which significantly contributes to survival prognosis.

This study explores the role of lead and cadmium in gynecological malignancies, focusing on their ability to mimic estrogen and induce oxidative stress, contributing to cancer development. It highlights their potential as biomarkers for early detection and treatment.

This study explores how the concentration of heavy metals, particularly zinc and copper, in the blood of ovarian cancer patients correlates with their recurrence-free survival. It highlights the potential of these metals as biomarkers for prognosis and suggests environmental factors play a role in cancer outcomes.

This review explores the role of the microbiome in ovarian cancer, focusing on microbial dysbiosis and bacterial metabolites that influence inflammation and carcinogenesis. It highlights the potential of microbiome-based therapies, such as probiotics and antibiotics, to improve treatment outcomes and provide new diagnostic tools.

This review explores the ovarian cancer-associated microbiome’s role in shaping the inflammatory microenvironment of tumors. It discusses how microbial dysbiosis and its metabolites contribute to cancer progression, immune suppression, and therapeutic resistance, suggesting microbiome modulation as a potential therapeutic strategy.

This review explores how the microbiome influences ovarian cancer development, progression, and treatment response. It emphasizes microbial dysbiosis as a factor in carcinogenesis and offers insights into therapeutic opportunities like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review examines how the aging gut microbiome affects ovarian cancer progression. It highlights microbial dysbiosis as a common feature in both aging and cancer, with implications for novel therapeutic strategies like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review highlights the role of vaginal microbiota in ovarian cancer carcinogenesis, progression, and treatment. It discusses microbial dysbiosis and potential therapeutic interventions like probiotics and vaginal microbiota transplantation, offering promising avenues for improving cancer treatment.

This review highlights the significant role of the female reproductive tract microbiome in the development of gynecological cancers, focusing on microbial dysbiosis, estrogen regulation, and potential therapeutic strategies.

This review examines the role of the microbiome in gynecologic cancer development and treatment, emphasizing its potential for early diagnosis and therapeutic modulation. The microbiome’s influence on chemotherapy and immunotherapy responses offers new avenues for cancer management.

This review explores the role of the microbiome in ovarian cancer, emphasizing its potential for early diagnosis and treatment. The use of microbiome-based biomarkers and therapies like fecal and vaginal microbiome transplantation offers promising new avenues for cancer care.

This study investigates the effects of ketogenic and high-fat diets on gut microbial composition and ovarian cancer progression in mice. It shows that high-fat diets increase tumor growth and disrupt microbial diversity, highlighting the potential role of diet in cancer therapy and prevention.

This review examines the relationship between diet and ovarian cancer risk, finding that animal fats and dairy are linked to higher risk, while vegetables and bioactive compounds may offer protective benefits, although results are inconsistent across studies.

This case-control study highlights the significant role of diet in ovarian cancer risk, with high vegetable and fruit intake reducing risk, while animal fats and salted vegetables increase it. Fried and smoked foods also contribute to a higher risk.

This review underscores the importance of diet and physical activity in modulating the gut microbiome of cancer patients. Diets like fiber-rich and Mediterranean diets show promise in improving cancer treatment outcomes. Exercise also enhances microbial diversity and immune function, potentially improving patient quality of life.

Probiotics were shown to significantly reduce cancer cell proliferation, promote apoptosis, and inhibit migration in breast and ovarian cancer cells, suggesting their potential as adjunctive cancer therapies.

This review maps advances in ovarian cancer management, from surgery and chemotherapy to targeted and emerging therapies, and highlights a need to integrate microbiome insights.

This review analyzes the global epidemiology and risk factors of ovarian cancer, emphasizing the role of genetic predispositions, reproductive factors, and lifestyle choices. It highlights the disparities in incidence and mortality rates across regions and calls for better prevention and early detection strategies.

This review discusses ovarian cancer diagnosis, molecular characteristics, and treatment strategies, emphasizing the role of targeted therapies like PARP inhibitors and immunotherapy, with a focus on personalized treatment approaches based on genetic and molecular tumor profiles.

This review covers the epidemiology, genetics, and molecular mechanisms of ovarian cancer, focusing on the role of estrogen receptors and genetic mutations such as BRCA1/2. It emphasizes the importance of genetic testing and the potential of targeted therapies, including PARP inhibitors, for improving patient outcomes.

This review discusses liquid biopsy techniques for early ovarian cancer detection, focusing on circulating tumor cells, cell-free DNA, and extracellular vesicles. It highlights their potential to improve sensitivity, specificity, and prognosis prediction, providing a promising avenue for non-invasive cancer screening.

This review explores the molecular mechanisms of ovarian cancer metastasis, focusing on the role of stromal cells and the metastatic routes—passive dissemination and hematogenous spread—while discussing therapeutic implications for targeting both cancer cells and the tumor microenvironment.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study explored the role of hormone replacement therapy (HRT) in reversing gut microbiome and serum metabolome alterations in women with premature ovarian insufficiency (POI), identifying potential therapeutic targets for microbiome-based interventions.

This review explores butyrate’s role as a modulator in gynecological diseases, including PCOS, endometriosis, and cancer, highlighting its potential as a therapeutic agent through immune modulation, inflammation reduction, and cancer inhibition.

This paper explores how gut microbiota dysbiosis contributes to premature ovarian failure (POF) and highlights potential therapeutic interventions targeting GM for better management of POF.

This review explores how gut microbiota modulation influences ovarian aging and presents potential therapies like fecal microbiota transplantation and probiotics to prevent or alleviate ovarian aging, offering new strategies for preserving reproductive health.

This review examines the relationship between gut microbiota and ovarian aging, highlighting microbial dysbiosis as a key factor in ovarian function decline. It explores microbiota-based therapies like FMT to delay ovarian aging and discusses the role of dietary and pharmacological interventions.

This study demonstrates the effectiveness of ultrasound-guided hUC-MSC exosome injection in restoring ovarian function and fertility in POI rat models, offering a new therapeutic approach for women with POI.

This study demonstrates that metformin protects against chemotherapy-induced ovarian failure by reducing inflammation, oxidative stress, and senescence in granulosa cells via the AMPK/PPAR-γ/SIRT1 pathway.

The review discusses the therapeutic use of hormone replacement therapy (HRT) for managing POI and early menopause, highlighting its benefits in preventing complications like osteoporosis, cardiovascular disease, and depression.

This study identifies 27 metabolites linked to primary ovarian insufficiency (POI), revealing novel metabolic pathways and offering insights into POI biomarkers and therapeutic targets.

This study identifies 33 serum metabolites, including N-acetylalanine, linked to an increased risk of primary ovarian insufficiency (POI), offering new insights into the disease’s genetic and metabolic causes.

This study identifies metabolic disruptions in POI, including altered amino acid and lipid metabolism. Key metabolites such as acetoacetate and HDCA were found to be potential biomarkers, shedding light on the oxidative stress and mitochondrial dysfunction involved in POI.

This study examines the metabolic profile of women with premature ovarian insufficiency, finding significant changes in lipid and glucose metabolism. The results underscore the importance of early metabolic screening and management to reduce cardiovascular and metabolic risks associated with POI.

This study investigates the metabolic differences in women with premature ovarian insufficiency (POI), highlighting increased waist circumference, cholesterol, and glucose levels. It underscores the importance of early metabolic screening and management to address the elevated cardiovascular risk associated with POI.

This study identifies key metabolites altered in premature ovarian insufficiency (POI), including arachidonoyl amide and 18-HETE, which could serve as diagnostic biomarkers. The findings reveal insights into the metabolic disturbances of POI, offering potential therapeutic directions.

This study explores the potential link between serum heavy metal levels and premature ovarian insufficiency. The higher levels of metals like lead and mercury in women with POI suggest environmental toxins may contribute to ovarian dysfunction, though the findings were not statistically significant.

This review highlights the impact of heavy metal-induced oxidative stress on ovarian function, contributing to premature ovarian insufficiency. It discusses the mechanisms by which metals like copper, arsenic, and cadmium induce ROS, leading to ovarian damage, and the potential therapeutic role of antioxidants.

Tobacco smoke significantly impacts ovarian function, leading to premature ovarian insufficiency. The review outlines the harmful effects of various tobacco-related toxins, such as nicotine, cadmium, and PAHs, and the associated reproductive consequences, including early menopause and reduced fertility.

The review explores the potential of dietary supplements, including probiotics and phytoestrogens, to manage premature ovarian insufficiency (POI) symptoms. It highlights the safety, bioavailability, and efficacy of these nutrients for improving reproductive health and delaying ovarian function decline.

This study identifies dietary habits that influence the risk of Primary Ovarian Insufficiency (POI), finding that high-fat dairy products increase risk while oily fish and pork offer protection, suggesting that dietary interventions could help prevent POI.

The study reveals a distinct gut microbiome profile in women with premature ovarian insufficiency (POI), with altered bacterial populations linked to hormonal changes, suggesting a potential role of the microbiome in POI pathogenesis and management.

The study reveals that women with premature ovarian insufficiency on systemic hormone therapy maintain a Lactobacillus-dominated vaginal microbiome, similar to estrogenized women, though some show signs of bacterial vaginosis, indicating the influence of factors beyond estrogen.

This study identifies significant differences in vaginal microbiota between women with premature ovarian insufficiency (POI) and healthy controls, suggesting that microbial shifts could contribute to ovarian dysfunction and hormone imbalances in POI.

This study identifies significant differences in vaginal microbiota between women with Primary Ovarian Failure (POF) and healthy controls, highlighting the role of Lactobacillus species in reproductive health and suggesting potential microbiota-targeted interventions for POF.

The review examines how lifestyle factors like diet, exercise, and oxidative stress contribute to Premature Ovarian Insufficiency (POI) and explores potential interventions using antioxidants, phytoestrogens, and dietary changes.

This review provides a comprehensive look at the genetic and phenotypic aspects of Premature Ovarian Insufficiency (POI), emphasizing the roles of various genes and chromosomal abnormalities, and offering insights into personalized treatment options and future research directions.

This review explores the causes, clinical presentation, and management of Premature Ovarian Insufficiency (POI), highlighting the role of genetic, autoimmune, and environmental factors, and discusses advancements in fertility preservation and hormone replacement therapy.

This review investigates the genetic and non-genetic causes of Premature Ovarian Insufficiency (POI), highlighting recent advances in understanding its mechanisms and exploring novel therapeutic approaches such as hormone replacement therapy and stem cell treatments.

This review explores the genetic and clinical factors contributing to primary ovarian insufficiency (POI), highlighting key genes and the importance of early diagnosis, fertility preservation, and hormone replacement therapy.

Premature ovarian insufficiency (POI) leads to fertility issues, bone loss, cardiovascular risks, and cognitive decline. Early intervention, including hormone therapy and lifestyle changes, is vital for managing long-term health risks.

Primary Ovarian Insufficiency affects young women with amenorrhea and elevated FSH levels. It involves follicle dysfunction or depletion and requires comprehensive diagnosis and management, including hormone therapy and fertility preservation.

This review explores the pathophysiology, impact, and treatment of primary dysmenorrhea, emphasizing the role of prostaglandins and the significant effects on women’s quality of life. It highlights current pharmacological and non-pharmacological treatment options, suggesting a need for personalized, holistic approaches to management.

This review evaluates the potential therapeutic role of vitamins (D, E, B1, C, K) in reducing primary dysmenorrhea symptoms, proposing them as alternatives to NSAIDs, with promising results, particularly in inflammation and oxidative stress modulation.

This Cochrane review confirms that structured exercise markedly reduces menstrual pain in primary dysmenorrhea but reveals no microbiome data, prompting a call for studies linking exercise interventions with gut–uterine microbial signatures.

This review details how acupuncture and related therapies reduce inflammatory mediators, cytokines, chemokines, and leukocytes, to relieve primary dysmenorrhea, and underscores the need for microbiome-focused research.

This network meta‑analysis ranks six exercise modalities for primary dysmenorrhea, showing resistance and multi‑component training best reduce pain and symptoms, with clear dosage guidelines for clinical implementation.

This protocol outlines a systematic review and meta‐analysis plan to evaluate acupuncture, with or without moxibustion, for pain relief and safety in women with primary dysmenorrhea.

Vitamin D and calcium supplementation can significantly reduce primary dysmenorrhea symptoms and reliance on analgesics. The inverse relationship between serum vitamin D and calcium levels and dysmenorrhea severity supports their use as effective adjunct therapies.

A systematic review and meta-analysis showed that vitamin D supplementation effectively reduces primary dysmenorrhea pain, especially with doses over 50,000 IU weekly, with significant improvements in pain severity and serum 25(OH)D levels.

Yoga, especially asanas, pranayama, and yoga nidra, significantly reduces menstrual pain and distress in women with dysmenorrhea. These practices improve pain tolerance and overall well-being, offering a non-pharmacological alternative to traditional treatments.

Self-care interventions like exercise, heat, and acupressure significantly reduce menstrual pain in primary dysmenorrhea, with exercise showing the largest effect. These methods may be effective alternatives to medication.

Lactobacillus gasseri OLL2809 significantly reduced menstrual pain and dysmenorrhea in endometriosis patients, offering a potential non-hormonal alternative to traditional treatments. No adverse effects were reported.

Bovine lactoferrin shows promise as an adjunct for pain relief, enhancing opioid efficacy while reducing side effects. Its anti-nociceptive and anti-inflammatory actions warrant further research in clinical settings.

FeLf improved psychological symptoms related to menstrual distress, particularly autonomic balance, in healthy women. However, no significant effects on menstrual pain or quality of life were observed.

Nifedipine may provide significant pain relief for women with primary dysmenorrhoea, but evidence quality is low. Larger studies are needed to confirm its effectiveness and safety.

HIIT significantly improved pain and physical fitness in women with primary dysmenorrhea, while probiotics showed some benefits in alleviating premenstrual symptoms. However, probiotics alone did not impact hormone levels or inflammation.

Three-month probiotic supplementation improved mental health and reduced NSAID reliance in women with primary dysmenorrhea, though it did not alter inflammatory cytokines or directly measure microbiome changes.

This study links a snack‐heavy dietary pattern to a significantly higher risk of moderate to severe dysmenorrhea among young women, highlighting the importance of dietary counseling in menstrual pain management.

This study links specific elements of the Mediterranean diet, particularly fruit and olive oil intake, to menstrual pain and characteristics, highlighting potential roles for anti-inflammatory foods in menstrual health among Spanish university women.

Zinc supplementation significantly reduces pain severity in women with primary dysmenorrhea, especially with longer durations of use, offering a safe and effective treatment option.

This meta-analysis demonstrates that cigarette smoking increases the risk of dysmenorrhea, with both current and former smokers showing a significantly higher likelihood of experiencing menstrual pain. Smoking cessation could be an effective intervention to alleviate symptoms.

This study identifies a strong association between concurrent tobacco smoking and alcohol drinking and increased dysmenorrhea risk. It emphasizes the need for lifestyle modifications, such as smoking cessation and exercise, to reduce menstrual pain.

This study demonstrates that zinc supplementation, when combined with mefenamic acid, significantly reduces primary dysmenorrhea pain and incidence, offering a more effective treatment strategy than mefenamic acid alone.

This systematic review highlights elevated oxidative stress and potential antioxidant deficiencies in women with primary dysmenorrhea. While oxidative markers such as MDA and NO were significantly higher, the evidence on antioxidant status remains inconclusive, suggesting a need for further research into therapeutic interventions.

This review discusses inflammatory markers and therapeutic options in primary dysmenorrhea, focusing on prostaglandins, cytokines, and vasopressin, and evaluates treatments like NSAIDs, acupuncture, and physiotherapy.

This metabolomics study identifies ten urinary biomarkers linked to primary dysmenorrhea, providing insights into the metabolic disruptions that contribute to PD and suggesting potential new therapeutic targets.

This study links dysmenorrhea symptom phenotypes with distinct vaginal microbiome compositions, suggesting that microbiome imbalances contribute to more severe menstrual pain, which could be targeted in new treatments.

This study explores how graphene-based warm uterus acupoint paste (GWUAP) treats primary dysmenorrhea by regulating intestinal microbiota and metabolites, highlighting its potential as a non-drug alternative therapy.

This systematic review highlights the significant association between primary dysmenorrhea and depression, emphasizing the need for integrated care that addresses both physical and mental health in affected women.

This systematic review will investigate the relationship between dysmenorrhea and psychological distress, including depression, anxiety, and stress, aiming to provide insights into their bidirectional effects and improve clinical management strategies.

This study links dysmenorrhea to an increased risk of postpartum depression in Chinese women. It highlights the need for early PPD screening in women with a history of dysmenorrhea.

The study links adolescent dysmenorrhea patterns with adult endometriosis development. It suggests that early intervention, guided by dysmenorrhea frequency and onset, can reduce the risk of EMs and its associated complications, including infertility.

A GWAS study identifies a significant genetic association at the NGF gene locus on chromosome 1p13.2, which may explain variations in dysmenorrhea pain severity, suggesting potential new therapeutic targets for pain management.

Primary dysmenorrhea is a prevalent condition that affects many women, particularly in their younger years. This review discusses its pathophysiology, impact on quality of life, and treatment options, including pharmacological, non-pharmacological, and alternative therapies.

A bibliometric analysis of dysmenorrhea research from 1992 to 2022 reveals increasing global interest in its pathogenesis, treatment, and functional connectivity. It emphasizes the role of prostaglandins, nonsteroidal anti-inflammatory drugs, and traditional Chinese medicine in managing the condition.

Primary dysmenorrhea is a common and impactful condition affecting young women. This review explores its pathophysiology, symptoms, and treatment options to improve diagnosis and management in clinical practice.

Primary dysmenorrhea is a common, underdiagnosed condition that causes significant pain and affects women’s daily lives. The study highlights its pathophysiology, diagnostic approach, treatment options, and the need for greater awareness and research into its management.

Primary dysmenorrhea (PD) is painful menstrual cramps without underlying pelvic pathology, predominantly caused by elevated prostaglandins inducing uterine contractions and ischemia. Managing primary dysmenorrhea (PD) requires understanding its complex mechanisms involving prostaglandins, oxidative stress, and inflammation. Treatments include NSAIDs, hormonal therapies, and promising complementary options like probiotics, vitamins, omega-3 fatty acids, exercise, yoga, acupuncture, and massage, significantly improving women’s quality of life.

What was studied?This study examined the interaction between the vaginal microbiota and mycobiota in patients with vulvovaginal candidiasis (VVC). The research focused on understanding the role of different Candida species, specifically Candida albicans and Candida glabrata, in the pathology of VVC, and how they influence the vaginal bacteriome. The study aimed to identify the microbial […]

This study investigates the link between gut microbiota and postpartum depressive disorder (PPD), identifying specific microbiota changes that correlate with depressive symptoms and hormonal levels. These findings could provide biomarkers for diagnosing and treating PPD.

This study explores the differences in microbiomes across breast tissue, oral, and urinary sites in women with and without breast cancer. Key findings suggest distinct microbiomic patterns in cancerous tissue and the urinary microbiome, providing new insights into the role of microbiota in cancer development.

This study examined the impact of estrogen on oral health and microbiome composition in COVID-19 patients, showing that postmenopausal women and men experience poorer oral health, which correlates with elevated proinflammatory cytokines and lower ACE2 expression, potentially influencing COVID-19 outcomes.

This study explores the impact of vaginal microbiota on IVF outcomes in women with infertility. It highlights how specific bacteria like Lactobacillus iners and Pseudomonas spp. can predict IVF success or failure, offering potential insights for personalized ART treatments.

This pilot study links gut microbiome diversity with breast cancer risk factors and tumor characteristics, particularly in HER2+ tumors and those with early menarche. It suggests microbial alterations in these groups that may influence cancer development and risk.